User Support Reference Group

Page tree

Meeting Details

Date & Time: Thursday 24th July, 2025. 11am UTC

Objectives

  • Users' discussions about the SNOMED International Drug Model and National Drug Extension Model.

Attendees: Alejandro Lopez Osornio Monica Harry Yongsheng Gao Nicola Ingram Mia van Dorp Achyut Patil Venkata Aditya Parnandi Ana Paredes @Benny van Bruwaen Betania Arispe Claudie SombieDion McMurtrie Colin Macfarlane Emilie Nguyen Francois Lavoie @Ger Gahan Guillermo Reynoso Hui Pheng Teoh  Jaya Sonavane Justin Stout Joanna Hand Julie Boutin Karen Rees Krista Lilly Yongsheng Gao Linda Bird Oumaima Kharrat Marie-Alexandra Lambot @maria gomez Michael Keary @nick mcgraw Noelle Horan Olivia Dalleur Paul Wright Robert Wynne Stuart Abbott Tara Kelly Wei Zhou Yolaine Forget  


Zoom Link

Link: Join DEUSG Zoom Meeting

Meeting Recording

Recording: https://snomed.zoom.us/rec/share/ZIOr6Z49IpZ20n8HN8t-Q2YVMUcyp4GJSb13NvLeM29DFWmx-5AV5wCE6rkWv84w.-4Yqr9rPkUQaijoI

Passcode: $tokT5pk

Discussion items

Item

Description

Mins

Owner

Notes & Actions

1Opening2
 Alejandro Lopez Osornio

Welcome & Notification of Recording

2Substances Co-Ordination10
Krista Lilly 
Workshop/Clinic to support queries from countries currently undergoing reviews in advance of promotion. Policies related to substance submissions during this project.  Substances Co-ordination
3Implementation of Routes of Administration for medicines15

Mia van Dorp 

Update from New Zealand on Implementation of Routes of Administration

Presentation: 

4Editorial advice for PCDs PTs10

Alejandro Lopez Osornio Karen Rees 

Consultation received from members about improving the guidance on this topic

5

Drug Administration vs Therapy

10

Nicola Ingram 

Highlight discussion topic

6AOB2Alejandro Lopez Osornio 

Prioritize backlog for next steps

Next meeting: August 7th, 2025

Antwerp 2025:

7Topic Backlog

  • Less Granular Clinical Drug
  • Elemental Substances (Matt, AUS)
  • Substances Co-ordination
    • Step 1: Substances in multiple extensions Batch promotions complete, SI review and authoring underway
    • Step 2: Substances in one extension
    • Step 3: Ongoing Substance Co-ordination (capturing at regulator level)
  • Medication Stopped v Medication Discontinued (Karen, SI)
  • Medicinal Product promotion co-ordination (Oslo group discussion as linked to substances work + ES)
  • Value range of a |Has container type| attribute (Linda, CA)
  • Top level children of 373873005 |Pharmaceutical / biologic product| hierarchy - are members using/how are members using? (AUS) 
  • Routes of Administration - Implementation Considerations (Mia, NZ)
  • Increase range of has active ingredient to include microorganisms and natural products (Guillermo)
  • Link between Substances and the organism they come from (Cat dander protein → Cat organism) see PCP-68


Done or in progress:

  • Hydration Subsumption 'Option 3' proposed by DEUSG for communication/consultation with MAG and EAG
  • Group Input on Patch Strength Representation Briefing note now being implemented
  • Dose Form Intended Site v Route of Administration (BEL) Pending implementation use-cases associated with intended site
  • Drug extension MRCM attributes (CA, AUS) SI facilitating links with CA and AUS for cross-promotion, next steps: other countries to be invited to add to catalogue

  File Modified
PDF File NZ Route of administration exploration.pdf 2025-Jul-23 by Alejandro Lopez Osornio

  • No labels